Jasper Therapeutics Analyst Ratings
BenzingaApr 3 07:32 ET
Jasper Therapeutics Analyst Ratings
BenzingaMar 28 04:35 ET
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
TipRanksMar 20 09:05 ET
Analysts' Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
TipRanksMar 20 09:00 ET
Jasper Therapeutics Analyst Ratings
BenzingaMar 18 08:33 ET
Buy Rating for Jasper Therapeutics: Promising Prospects for Briquilimab in Treating Chronic Urticaria
TipRanksMar 18 05:45 ET
Jasper Therapeutics Analyst Ratings
BenzingaMar 7 08:01 ET
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)
TipRanksMar 7 07:41 ET
Buy Rating Affirmed: Jasper Therapeutics' Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatment
TipRanksMar 4 13:15 ET
Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)
TipRanksFeb 27 07:48 ET
Buy Rating on Jasper Therapeutics Highlighting Briquilimab's Potential in Chronic Urticaria Treatment
TipRanksFeb 26 14:25 ET
Buy Rating for Jasper Therapeutics: Promising Developments in CSU Treatment Pipeline and Anticipated Clinical Milestones
TipRanksFeb 21 09:45 ET
Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target
BenzingaOct 12, 2023 11:50 ET
Jasper Therapeutics Analyst Ratings
BenzingaOct 12, 2023 11:46 ET
Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target
BenzingaAug 14, 2023 08:08 ET
Jasper Therapeutics Analyst Ratings
BenzingaAug 14, 2023 08:08 ET
Jasper Therapeutics Analyst Ratings
BenzingaAug 11, 2023 10:26 ET
EF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)
TipRanksJun 12, 2023 08:25 ET
EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target
BenzingaJun 12, 2023 07:15 ET
EF Hutton Assumes Jasper Therapeutics at Buy, Announces Price Target of $6.85
BenzingaMay 25, 2023 07:06 ET
No Data
No Data